Ping An Biomedical Co., Ltd.
PASW Nasdaq Apparel & Other Finishd Prods Of Fabrics & Similar Matl Financials FY2023–FY2025
What Ping An Biomedical Co., Ltd. does
No business description yet.
- Legal name
- Ping An Biomedical Co., Ltd.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 20-F · Jan 30, 2026
- Accession · CIK
- 0001213900-26-010078
0001897532
Revenue and margins
Ping An Biomedical Co., Ltd. had $4.7M of revenue in fiscal 2025, down 61.1% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Ping An Biomedical Co., Ltd. returned — to shareholders in fiscal 2025. The diluted share count rose 2.7%.
Balance sheet
Cash, debt and the ratios that show how comfortably Ping An Biomedical Co., Ltd. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $0.1M | $0.0M | $0.2M |
| Debt incl. finance leases | — | $1.4M | $1.4M |
| Net debt / EBITDA | — | 1,279.4x | — |
| Debt / equity | — | — | 0.2x |
| Interest coverage | 0.4x | −0.0x | −47.8x |
| Current ratio | — | 0.8x | 2.8x |
| Quick ratio | — | 0.8x | 2.7x |
| Total assets | — | $8.1M | $9.6M |
| Total liabilities | — | $9.1M | $3.3M |
| Shareholders' equity | −$0.8M | −$1.0M | $6.4M |
| Net debt (− = net cash) | — | $1.4M | $1.2M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✓ | ✕ |
| Return on assets rose | — | — | ✕ |
| Cash from operations exceeds net income | ✕ | ✓ | ✓ |
| Debt fell relative to assets | — | — | ✓ |
| Current ratio rose | — | — | ✓ |
| Share count didn't rise | — | ✓ | ✕ |
| Gross margin rose | — | ✓ | ✕ |
| Revenue rose relative to assets | — | — | ✕ |
| F-score | — / 3 | — / 5 | 3 / 9 |
| Accruals ratio | — | −27.2% | −10.0% |
| Altman Z'' | — | −1.77 | 3.52 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | $11.7M | $12.2M | $4.7M |
| Gross profit | $0.6M | $0.8M | $0.1M |
| Operating income | $0.1M | −$0.0M | −$2.0M |
| Interest expense | $0.2M | $0.1M | $0.0M |
| Pretax income | $0.0M | −$0.1M | −$2.0M |
| Income tax | −$0.1M | −$0.1M | $0.3M |
| Net income | −$0.1M | −$0.2M | −$1.8M |
| Diluted EPS | −$0.01 | −$0.01 | −$0.10 |
| Diluted shares | 0.02B | 0.02B | 0.02B |
| Cash flow | |||
| Cash from operations | −$0.9M | $2.0M | −$0.9M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M |
| Dividends paid | $1.4M | $0.0M | — |
| Dividends and buybacks | $1.4M | $0.0M | — |
| Balance sheet | |||
| Cash and short-term investments | $0.1M | $0.0M | $0.2M |
| Total debt | — | $1.4M | $1.4M |
| Current assets | — | $7.6M | $8.9M |
| Current liabilities | — | $9.1M | $3.2M |
| Inventory | — | $0.0M | $0.1M |
| Property and equipment, net | — | $0.0M | — |
| Total assets | — | $8.1M | $9.6M |
| Total liabilities | — | $9.1M | $3.3M |
| Shareholders' equity | −$0.8M | −$1.0M | $6.4M |
| Margins | |||
| Gross margin | 5.1% | 6.2% | 2.8% |
| Operating margin | 0.7% | −0.0% | −43.1% |
| EBITDA margin | 0.8% | 0.0% | −43.0% |
| Net margin | −1.2% | −1.5% | −37.6% |
| Returns | |||
| Return on capital | — | −0.1% | −21.2% |
| Return on capital employed | — | 0.0% | −32.0% |
| Return on equity | — | — | −66.7% |
| Return on assets | — | −2.2% | −20.1% |
| Return on tangible equity | — | — | −28.0% |
| Growth | |||
| Revenue growth | — | 3.9% | −61.1% |
| Share count change | — | 0.0% | 2.7% |
| Financial health | |||
| Net debt / EBITDA | — | 1,279.4x | — |
| Debt / equity | — | — | 0.2x |
| Interest coverage | 0.4x | −0.0x | −47.8x |
| Current ratio | — | 0.8x | 2.8x |
| Quick ratio | — | 0.8x | 2.7x |
| Quality scores | |||
| Piotroski F-score | — | — | 3.0 |
| Altman Z'' | — | −1.8 | 3.5 |
| Accruals ratio | — | −27.2% | −10.0% |
Source: SEC EDGAR XBRL filings (CIK 0001897532). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in CNY under US GAAP and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.